We additionally note that the inactive ingredients in a generic topical product need not match those in the RLD so long as the applicant “identifies and characterizes [any] differences and provides information demonstrating that the differences do not affect the safety or efficacy of the proposed drug product.” 21 CFR 314.94(a)(9)(v). In